Medtecs boom!

Only 1 million shares traded so far at 1030 am. Stock at $1.19, expected PE about 5X or less for this year's earnings.


Shortists finally staying away-- or they will get burned -- because fantastic 3Q results will be released some time next week.

Buyers not so many either as those who want to can see the undervaluation of the stock have already done bought in, and positioned themselves for 3Q results.

Funds are the missing creatures. Probably they need to access management after 3Q for clarity.

3Q profit to be announced this week will be huge, hopefully. Will catch the eye of institutional investors. The thing about insti is, as Rodknight buddy says, they don’t just look at one or two quarters of excellent results....the 3rd qtr and 4th qtr results and outlook are crucial imho. by then how many of us are still in this stock if the institutional investors come? Hence, i thjnk if we want supernormal profits, must think big and far.....not everyday worry abt contra traders or shortists.

Medtecs has guided that 4Q profit will be higher than 3Q. Thus, conservatively, the minimum 4Q profit and FY20 profit are as follows:

1. commenced operations in the Philippines in 1989 and has since established a strong presence in the United States, Europe, and Asia Pacific.

2. offices and facilities spanning across Asia - in Singapore, Taiwan, the Philippines, the People's Republic of China ("China"), and Cambodia.

3. listed in Singapore on October 6, 1999.

4. The Group's Taiwan Depository Receipts were listed on the Taiwan Stock Exchange (TWSE) on December 13, 2002.

Thursday, 212,000 shares naked short-sell.
T+2, today, Monday, Kana SGX buy-in at higher prices.
Plus CDP charges a processing fee of S$75.00 (S$80.25 inclusive of GST) for each failed contract.
+ brokerage rate of 0.75% .



SGX buy-in details: links.sgx.com/FileOpen/Buying-InSecuriti...cement&FileID=639376